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A certain level of attention to bodily signals may be adap-
tive in the management of chronic skin conditions, as a 
lack of attention may lead to inadequate self-care beha-
viour and, consequently, may affect functioning and tre-
atment outcomes. The purpose of this study was to deve-
lop a body awareness questionnaire and to investigate its 
psychometric properties and physical and psychological 
correlates in a cross-sectional study in patients with pso-
riasis (n = 475). The 16-item Body Attention, Ignorance 
and Awareness Scale demonstrated a 3-factor structure 
that could be interpreted as body ignorance, body atten-
tion, and body awareness (Cronbach’s α of 0.73, 0.74, 
and 0.68, respectively). Higher body ignorance was sig-
nificantly related to more physical symptoms and wor-
se psychological functioning. Body attention and body 
awareness showed small significant correlations with 
coping and personality. Given the negative influence of 
impaired psychological functioning on treatment outco-
mes, it may be clinically important to screen for theses 
constructs of body awareness in chronic skin conditions. 
Key words: psoriasis; body awareness; patient-reported 
outcome; chronic skin conditions; compliance and adhe-
rence; health psychology.
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Having a chronic skin condition can have negative conse-
quences for physical as well as psychological wellbeing 
(1–4). One of the major problems that patients have to 
cope with is itch, which accompanies the majority of 
dermatological diseases (5–10). The prevalence of itch 
ranges from 50% up to 92% in patients with chronic 
skin conditions (6–10). Physical symptoms such as itch 
are known to significantly affect patients’ quality of life 
(5–7) and are associated with emotional distress (5, 7, 
9, 10). In order to manage their chronic skin condition, 
patients are often required to take an active role in their 
treatment; the majority of patients need to use topical 
treatments on a regular basis to prevent deterioration. As 
better treatment adherence generally results in greater im-
provement, adequate self-care behaviour is very relevant 
in these patients (11). In order to respond to symptoms of 
the skin condition with appropriate self-care behaviour, 
patients should be aware of the bodily signals that indicate 
that self-care is required. Thus, the way in which people 
pay attention to and interpret bodily signals, which is an 
important aspects of body awareness, may be relevant, 
especially in patients with chronic skin conditions. 
Body awareness can be defined as an attentional focus 
on, and awareness of, body sensations (12). In previous 
research, heightened body awareness has been viewed 
mainly as a mechanism that may be detrimental to 
health and wellbeing (13, 14) as it may lead to exces-
sive worrying about physical symptoms and somatizing 
thoughts. These findings originated partly from findings 
regarding health anxiety (excessive concern about one’s 
health; 15) and hyper-vigilance (heightened attention; 
e.g. 16) to bodily symptoms, both of which are as-
sociated with an increased attention to bodily signals, 
high levels of symptom reporting, and negative health 
outcomes (e.g. 17). Recently, however, an alternative 
view has emerged that perceives body awareness as an 
adaptive process that may be useful in the management 
of chronic conditions, as long as body awareness invol-
ves mindful attentiveness to the present moment and not 
excessive worrying about symptoms (12, 13, 18, 19). 
Even though they are different constructs, both alexi-
thymia, which is characterized by the inability to iden-
tify and verbalize emotions (20), and body awareness 
show similarities, in the sense that they share a focus 
on internal awareness processes. Previous research has 
found moderately negative associations between alex-
ithymia and body awareness (21–23), suggesting that a 
lack of ability to identify and verbalize emotions may 
be related to a lack of awareness of physical sensations. 
In samples of dermatological patients, a certain level 
of body awareness may lead to patients paying adequate 
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attention to bodily symptoms such as dry skin and, 
resultantly, to taking appropriate action, such as using 
moisturizing ointments. Subsequently, the lack of body 
awareness, especially, could be detrimental for patients 
with a chronic skin condition. For instance, patients who 
do not pick up subtle bodily signals, such as dry skin 
or itch, may not take care of their skin accordingly and 
thus are less able to control their skin condition through 
adequate skin care. Finally, there are some indirect in-
dications that body awareness interventions may have 
positive effects on wellbeing for chronic skin condi-
tions. For instance mindful awareness, which includes 
elements of body awareness, may be of relevance for 
chronic skin conditions; a brief attention intervention 
focusing on mindful meditation has shown to accelerate 
the rate of clearance in psoriasis patients undergoing 
photo(chemo)therapy (24, 25). Although these results 
are based on a small study in need of replication, they 
indicate that (mindful) aspects of body awareness may 
play a role in alleviating physical symptoms in chronic 
skin conditions such as psoriasis.
A systematic review examined existing self-report 
measures for body awareness and concluded that they 
often lacked adequate psychometric properties and 
were often unidimensional, leaving out key aspects 
of body awareness (12). The authors of this review 
recently constructed a new, relatively elaborate mea-
sure of body awareness consisting of 8 subscales as an 
alternative (18, 26). However, this measure does not 
include items regarding a specific lack of attention to, 
or ignorance of, bodily signals, which is hypothesized 
to be important in dermatological patient samples. The 
current study aims to: (i) assess a conceptualization of 
body awareness including ignorance of bodily signals in 
psoriasis patients by means of a new brief scale suitable 
for dermatological patient groups; and (ii) examine its 
psychometric properties and correlations with measures 
of physical and psychological functioning, personality 
characteristics, coping, and illness cognitions.
MATERIALS AND METHODS
Participants and procedure 
In order to prevent selection bias, patients were recruited from 
both academic (Radboud university medical center, Nijmegen, 
The Netherlands) and non-academic (Canisius-Wilhelmina 
Hospital, Nijmegen; Rijnstate Hospital, Velp; Ziekenhuis 
Groep Twente, Almelo, The Netherlands) hospitals, as well as 
from the Dutch Psoriasis Association. Inclusion criteria were: 
a minimum age of 18 years and a dermatologist-confirmed pso-
riasis diagnosis. Exclusion criteria were: illiteracy, pregnancy, 
presence of other physical conditions that had a larger perceived 
impact on the daily life than psoriasis, presence of psychiatric 
comorbidity (according to the Diagnostic and Statistical Ma-
nual of Mental Disorders; 27) and/or current psychological 
treatment. The study protocol was approved by the regional 
medical ethics committee and written informed consent was 
obtained from each participant. The current study was part of a 
larger study examining the effectiveness of E-health cognitive 
behavioural therapy for patients with psoriasis, and made use 
of questionnaires that were assessed as part of the screening 
procedure. All participants who completed questionnaires in 
the period March 2010–May 2013 were included. The resulting 
sample size of 475 can be considered (highly) sufficient ac-
cording to often-cited sample size guidelines for factor analysis 
(28). Sociodemographic characteristics of participants are 
shown in Table I. Participants’ mean ± SD age was 52 ± 13 years 
and gender was approximately evenly distributed (56% male). 
Disease severity was mild to moderate (29). Approximately half 
of our sample (46%) reported medical conditions in addition to 
psoriasis, of whom 32% indicated more than one other medical 
condition. Most commonly reported conditions were: rheu-
matic disease (100 of 220 patients; 45%), high blood pressure 
(n = 27; 12%), heart disease (n = 28; 13%), lung disease (n = 26; 
12%), diabetes (n = 26; 12%), chronic back/muscle/tendon pain 
(n = 21; 9.5%), skin disease besides psoriasis (n = 20; 9%), and 
thyroid disease (n = 14; 6%).
Item generation and scale construction
Based on a review of the literature, an item pool was gene-
rated with (adjusted) items of the following questionnaires: 
Bermond-Vorst Alexithymia Questionnaire (BVAQ; 20), 
Toronto Alexithymia Scale (TAS-20; 30), Body Awareness 
Questionnaire (BAQ; 31), Kentucky Inventory of Mindfulness 
Skills (KIMS; 32), Mindful Attention Awareness Scale (MAAS; 
33) and Amplification Questionnaire (APQ; 34). Items were 
adjusted to suit the revised conceptualization of body atten-
tion and ignorance (12). For instance, suitable items from 
the identifying, analyzing, and verbalizing dimensions of the 
alexithymia questionnaires were rephrased to reflect (a lack of) 
body awareness instead of a lack of emotional awareness (e.g. 
“I don’t know what’s going on inside my body” instead of “I 
don’t know what’s going on inside me” (TAS-20)). In 4 cases, 
original items were used. Initial item selection was conducted 
by 3 medical psychologists with a research and/or clinical focus 
on psychodermatology. The resulting item pool was sent to 5 
other clinicians and researchers involved in the field of psycho-
dermatology and to 3 patients involved in patient participation 
for dermatological research, with the instruction to evaluate the 
items on relevance, clarity and readability. This process led to a 
23-item scale comprising 14 indicative (positively formulated) 
Table I. Sociodemographic characteristics of the study population 
(n = 475)
Characteristics
Sex, n (%)
Male 266 (56) 
Female 209 (44)
Age, years, mean ± SD (range) 52.08 ± 13.06 (18–84)
Marital status, n (%)
Single 56 (12)
Married/living together 380 (80)
Divorced 22 (5)
Widowed 17 (4)
Educational level, n (%)
Primary education 72 (15)
Secondary education 226 (48)
Tertiary education 175 (37)
Missing 2 (0.4)
Disease severity (SAPASI), mean ± SD (range) 5.12 ± 4.03 (0–33)
Disease duration, years, mean ± SD (range) 16.00 ± 14.95 (0–64)
SAPASI: Self-Administered Psoriasis Area and Severity Index; SD: standard 
deviation.
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and 9 contra-indicative (negatively formulated) items (Table II). 
Respondents were asked to indicate on a 4-point Likert scale 
to what extent they agree with each statement (1 = not at all, 
2 = somewhat, 3 = to a large extent, 4 = completely). 
Measures of physical and psychological functioning
The following commonly-used and well-validated self-report 
questionnaires were used to examine correlations of body 
awareness with physical and psychological functioning and 
provide first indications of construct validity: 
Physical and psychological wellbeing. The Impact of Chronic 
Skin Disease on Daily Life (ISDL; 35) was used to measure 
physical functioning (itch, pain, and scratching behaviour). 
Symptoms of itch were assessed by means of a 4-item subscale 
measuring the intensity and duration of itch during the past 4 
weeks (Cronbach’s α in current study = 0.92). The answers are 
indicated on a 4-point Likert scale (ranging from “not at all” 
to “completely”) and higher scores indicate higher levels of 
itch. Pain was assessed on a 10-point VAS scale (0 = no pain, 
10 = worst pain ever experienced). Scratching behaviour was as-
sessed with 2 subscales: a 3-item conscious scratching subscale 
that assesses the frequency and duration of scratching beha-
viour (Cronbach’s α = 0.79) and a 3-item automatic scratching 
subscale that evaluates scratching behaviour to non-itching 
stimuli and scratching in the absence of itch or without being 
aware of it (Cronbach’s α = 0.71). In both scales, higher scores 
reflect more scratching behaviour.
The 8-item fatigue subscale of the Checklist Individual 
Strength (CIS; 36) was used to assess fatigue. The subscale con-
sists of 8 items that are responded to on a 7-point Likert scale 
(ranging from “yes, that is true” to “no, that is not true”), with 
higher scores reflecting more fatigue (Cronbach’s α = 0.94).
The Self-Administered Psoriasis Area and Severity Index 
(SAPASI; 37) was used to assess disease severity. On anterior 
and posterior silhouettes, patients mark the areas that are cur-
rently affected by psoriasis. Below the silhouettes, patients can 
note the redness, thickness, and scaliness of their psoriasis on 
3 analogue scales. Scores on the SAPASI can range from 0 
(complete remission) to 72 (most severe psoriasis). The SAPASI 
has shown good reliability and validity (37, 38).
The Dermatology Life Quality Index (DLQI; 39) is a derma-
tology-specific instrument used to measure quality of life. The 
questionnaire assesses the impact of chronic skin conditions 
on several physical, psychological, and social aspects of daily 
life. It consists of 10 items that are responded to on a 4-point 
scale (ranging from “very much” to “not at all”). Higher scores 
reflect poorer quality of life (Cronbach’s α = 0.85).
The Hospital Anxiety and Depression Scale (HADS; 40) was 
used to assess anxiety (7 items; Cronbach’s α = 0.82) and depres-
sion (7 items; Cronbach’s α = 0.80). The questions refer to the 
mood in the last week and they are responded to on a 4-point 
scale. Higher scores reflect higher levels of anxiety and depression. 
Coping. Two subscales of the Utrecht Coping List (UCL; 41) 
were used to assess active coping (problem-focused coping, 
7 items, Cronbach’s α = 0.83) and passive coping (avoidance 
strategies, 8 items, Cronbach’s α = 0.71) related to handling 
everyday stressful events. Respondents answer on a 4-point 
Likert scale (from “seldom or almost never” to “very often/
frequently”). Higher scores reflect a stronger tendency to use 
that specific coping strategy.
Illness cognitions. The Illness Cognition Questionnaire (ICQ; 
42) was used to measure illness cognitions related to chronic 
diseases: helplessness (concentration on aversive aspects of 
the disease), acceptance (positive adaptation to chronic illness 
with emphasis on decreasing its negative aspects), and per-
ceived benefits (assigning positive meaning to illness). Each 
subscale consists of 6 statements answered on a 4-point Likert 
scale (from “not at all” to “completely”), with higher scores 
indicating higher levels of the illness cognition. The ICQ was 
found to be highly reliable in the current sample (Cronbach’s 
α = 0.88 for each scale). 
Personality traits. The Eysenck Personality Questionnaire 
(EPQ; 43) was used to evaluate the personality traits neuro-
ticism (Cronbach’s α = 0.92) and extraversion (Cronbach’s 
α = 0.87). It consists of 41 items with a dichotomous response 
format (yes/no), with higher scores reflecting higher levels of 
the personality trait. 
Table II. Rotated factor loadings of the 3-factor solution for the Body Attention, Ignorance and Awareness Scale (BAIAS)
Items
Body 
ignorance
Body  
attention
Body 
awareness
Factor I
1. I do not know what is happening inside my bodya 0.68 –0.05 0.00
2. When I am not feeling well physically, I do not know the reasonb 0.64 0.17 0.10
3. I have physical sensations that I can’t quite identifya 0.63 –0.22 0.02
4. I do not know what is going on in my bodyb 0.62 0.16 –0.16
5. I am often confused about what I observe in my bodya 0.62 –0.11 –0.14
6. I find it difficult to describe my physical sensationsb 0.59 0.23 0.09
7. I tend not to notice feelings of physical tension or discomfort until they really grab my attentionc 0.55 0.19 0.17
Factor II
8. I notice changes in my body, such as whether my breathing slows down or speeds upd –0.04 0.72 0.12
9. I notice when my physical sensations are beginning to changed 0.17 0.69 0.17
10. I pay attention to whether my muscles are tensed or relaxedd 0.03 0.67 0.19
11. I know in advance when I am getting the flue 0.02 0.66 0.10
12. I know I am running a fever without taking my temperaturee 0.08 0.65 0.09
Factor III
13. I think that you should pay attention to your bodyb 0.01 0.05 0.76
14. When my body feels tense, I want to know where this feeling comes fromb –0.11 0.08 0.68
15. In general I pay attention to my physical sensationsd 0.21 0.31 0.68
16. It is important that you are aware of your bodya 0.01 0.28 0.64
% of variance explained 23.0 16.0 8.4
Item adapted from: aTAS-20 (Toronto Alexithymia Scale), bBVAQ (Bermond-Vorst Alexithymia Questionnaire), cMAAS (Mindful Attention Awareness Scale), 
dKIMS-obs (Kentucky Inventory of Mindfulness Skills – observe subscale), eBAQ (Body Awareness Questionnaire). Factor loadings  ≥ 0.55 printed in bold.
Acta Derm Venereol 95
447Body Attention, Ignorance and Awareness Scale
Statistical analysis
Exploratory factor analysis (EFA) with Varimax rotation and 
Kaiser normalization was performed to assess the underlying 
structure of the new questionnaire (44). Selection of the number 
of factors for the most optimal solution was based on conjunctive 
criteria requiring the eigenvalue of a factor being at least 1.0 and 
a clear bend in Cattell’s scree test (45). To assess the reliability 
of the new questionnaire, Cronbach’s α were computed for the 
3 scales. To examine associations between body awareness and 
measures of physical and psychological functioning and sociode-
mographic characteristics, Pearson correlation coefficients were 
computed for measures of physical and psychological wellbeing, 
personality characteristics, coping, illness cognitions, and socio-
demographic characteristics. Statistical significance was accepted 
at p < 0.05 in two-tailed tests. All analyses were performed using 
Statistical Packages for the Social Sciences version 20.0 (46). 
RESULTS
The newly developed 23-item questionnaire was sent 
to 682 psoriasis patients, 475 of whom returned the 
questionnaire (70% response rate). Missing values 
on this questionnaire were present in 1% of data and 
were randomly distributed. Missing values were pre-
sent in 1.6% of data in the entire dataset of included 
questionnaires (excluding the DLQI, as this scale was 
not distributed to the entire sample). Due to their low 
percentage and random distribution, the impact of these 
missing values is considered to be negligible. No cases 
with extreme values on one or more variables were 
observed; all values were within 3 standard deviations 
of the mean and all variables were normally distributed 
(skewness and kurtosis < 1.1). 
Exploratory factor analysis of the Body Attention, 
Ignorance and Awareness Scale
The 23 items of the original questionnaire were re-
duced to 16, based on examination of item loadings 
and cross-loadings (i.e. primary factor loadings > 0.50 
and at least 0.20 difference in cross-loadings; 6 items 
removed based on these criteria), meaningfulness and 
usefulness for the corresponding factor (1 additional 
item removed). Based on these 16 items, 3 factors were 
extracted, explaining a total of 47.4% of the variance. 
The resulting questionnaire was termed the Body At-
tention, Ignorance and Awareness Scale (BAIAS). The 
first component, “Body Ignorance” (not recognizing 
and/or ignoring bodily signals), explained 23.0% of 
the variance, the second component, “Body Attention” 
(being aware of and paying mindful attention to bodily 
signals), added 16.0% and the third component, “Body 
Awareness” (self-perceived importance of and general 
attitude towards body awareness), added 8.4%. 
Body Attention, Ignorance and Awareness scale: means 
and associations with sociodemographic variables
Based on the above-mentioned components, mean sco-
res on the 3 scales were calculated by adding the scores 
of the items and dividing them by the total number of 
items of that scale. If more than one-third of the items 
on 1 particular scale were missing, the mean score of 
the scale was not calculated. Mean scores on BAIAS 
scales for the total sample, and stratified by age, gender, 
educational level, and marital status are shown in Table 
III. Women scored slightly higher than men on Body 
Awareness (t(469) = –2.61, p < 0.01), no gender diffe-
rences were found for the other 2 scales. Patients with a 
higher educational level scored lower on Body Ignorance 
(F(2,452) = 13.98, p < 0.001) and higher on Body Atten-
tion (F(2,452) = 8.78, p < 0.001) and Body Awareness 
(F(2,453) = 3.78, p = 0.02). No differences according to 
age group or marital status were found for any of the 3 
scales, nor were the subscales of the BAIAS significantly 
correlated with age (continuous scores; p-values ≥ 0.36).
Table III. Mean scores on the Body Attention, Ignorance and Awareness Scale (BAIAS), stratified by age, gender, education, 
and marital status
Body ignorance 
Mean ± SD
Body attention 
Mean ± SD
Body awareness  
Mean ± SD
Total sample 13.59 ± 3.51 (n = 470) 12.32 ± 3.31 (n = 470) 11.61 ± 2.26 (n = 471)
Stratified by age
18–44 13.40 ± 3.45 (n = 127) 12.02 ± 3.35 (n = 127) 11.67 ± 2.17 (n = 126)
45–64 13.49 ± 3.61 (n = 261) 12.52 ± 3.31 (n = 260) 11.54 ± 2.30 (n = 262)
65–84 14.18 ± 3.27 (n = 82) 12.15 ± 3.23 (n = 83) 11.74 ± 2.28 (n = 83)
Stratified by gender
Male 13.76 ± 3.67 (n = 262) 12.35 ± 3.28 (n = 261) 11.37 ± 2.24** (n = 263)
Female 13.37 ± 3.30 (n = 208) 12.28 ± 3.35 (n = 209) 11.91 ± 2.25** (n = 208)
Stratified by education
Primary 15.00 ± 2.93*** (n = 71) 10.85 ± 3.42*** (n = 72) 10.93 ± 2.43* (n = 72)
Secondary 13.82 ± 3.32*** (n = 219) 12.61 ± 3.26*** (n = 218) 11.69 ± 2.29* (n = 219)
Tertiary 12.59 ± 3.61*** (n = 165) 12.58 ± 3.16*** (n = 165) 11.75 ± 2.13* (n = 165)
Stratified by marital status
Married/long-term relationship 13.51 ± 3.53 (n = 398) 12.24 ± 3.21 (n = 399) 11.61 ± 2.22 (n = 400)
Single 14.07 ± 3.42 (n = 71) 12.67 ± 3.79 (n = 70) 11.61 ± 2.52 (n = 70)
*p < 0.05; **p <0.01; ***p <0.001.
SD: standard deviation.
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Reliability and intercorre lations of the Body Atten tion, 
Ignorance and Aware ness Scale 
The internal consistency was satisfactory for the Body 
Ignorance (α = 0.73), Body Attention (α = 0.74) and Body 
Awareness (α = 0.68) scales of the BAIAS. The subscale 
Body Attention showed a moderate correlation with the 
subscale Body Awareness (r = 0.43, p < 0.001), and the 
Body Ignorance and Body Attention subscales were 
slightly, but significantly, negatively correlated (r = –0.16, 
p < 0.001). No significant correlation was found between 
the Body Awareness and Body Ignorance subscales 
(r = –0.08, p = 0.09).
As reported in Table IV, higher levels of Body Igno-
rance were associated with higher levels of itch, pain, 
and fatigue, more scratching, a decreased quality of 
life, higher levels of anxious and depressive symptoms, 
more avoidant coping, less active coping, higher levels 
of neuroticism and helplessness, and lower levels of 
extraversion and acceptance. Correlations between the 
Body Attention subscale and measures of physical and 
psychological wellbeing were mostly non-significant, 
with the exception of small correlations of higher Body 
Attention with higher levels of active coping, accep-
tance, and extraversion. Similarly, small correlations 
were found for higher Body Awareness, with higher 
levels of active coping and higher levels of anxiety, 
neuroticism and extraversion. 
DISCUSSION
The aims of the current study were to develop a 
measure to assess body awareness and to examine its 
physical and psychological correlates in patients with 
psoriasis. The results showed that body awareness can 
be measured adequately in patients with psoriasis by 
means of the BAIAS. In addition, body ignorance and, 
to a lesser extent, body awareness and attention were 
related to physical and psychological functioning. In 
particular, patients who do not recognize and/or ignore 
their bodily signals experience lower levels of physical 
and psychological wellbeing. The BAIAS showed a 
3-factor structure, with 3 reliable scales – body igno-
rance (not recognizing and/or ignoring bodily signals), 
body attention (being aware of and paying mindful 
attention to specific internal bodily signals) and body 
awareness (self-perceived importance of and general 
attitude towards body awareness). In line with our hy-
pothesis, the aspect of the BAIAS reflecting a low level 
of body awareness demonstrated associations with poo-
rer physical and psychological wellbeing. Higher levels 
of body attention and body awareness were not related 
to physical and psychological wellbeing, but slightly 
to aspects of coping and personality that are generally 
perceived as adaptive (active coping and extraversion). 
We explicitly added items in the BAIAS that assess the 
failure to recognize bodily signals, which was shown 
to be only slighly negatively correlated with body 
attention. Results suggest that body awareness is not a 
unidimensional construct, but rather consists of multi-
ple aspects that may be independently associated with 
physical and psychological functioning. The concepts 
of body awareness and body ignorance seem to have 
inherently different meanings. While body awareness 
refers to the general tendency to be aware of and pay 
attention to bodily signals, body ignorance is related 
more to not recognizing or to actively ignoring bodily 
signals. Several mechanisms can be suggested to play 
a role in both concepts. For example, parallels can 
be drawn between body ignorance and the emotion 
regulation strategies of avoidance and suppression, 
which were found to be related to psychopathology in 
meta-analysis with moderate to large effect sizes (47). 
Body ignorance may also be related to the maladap-
tive emotion regulation construct of “experimental 
avoidance”; the suppression or avoidance of a broader 
range of psychological experiences, including bodily 
signals, but also, for instance, cognitions, emotions, 
memories and sensations (48, 49). Body ignorance 
might be related to problems with adherence; bodily 
signals often have a certain threat value due to signals 
of disease, and are therefore potentially avoided or 
ignored in patients who score high on body ignorance. 
Table IV. Correlations between the Body Attention, Ignorance 
and Awareness Scale (BAIAS) and measures of physical and 
psychological functioning 
Measure
Body 
ignorance
Body 
attention
Body 
awareness
r n r n r n
Physical and psychological wellbeing
Itch 0.20*** 466 0.00 465 0.06 466
Pain 0.24*** 461 –0.05 461 0.03 462
Fatigue 0.32*** 468 –0.04 468 0.01 469
Conscious scratching 0.18*** 451 –0.05 451 0.03 452
Automatic scratching 0.12* 451 –0.05 451 0.06 451
Quality of life 0.25*** 362a 0.02 362a 0.03 362a
Disease severity 0.06 448 0.00 449 0.05 449
Depression 0.33*** 467 –0.04 467 –0.07 469
Anxiety 0.34*** 468 0.01 468 0.11* 469
Coping
Active –0.24*** 465 0.27*** 465 0.18*** 466
Passive 0.29*** 466 –0.07 466 –0.06 467
Illness cognitions
Helplessness 0.30*** 467 0.04 466 0.02 467
Acceptance –0.24*** 467 0.10* 466 0.02 467
Perceived benefits 0.10* 464 0.07 463 0.07 464
Personality traits
Neuroticism 0.33*** 469 –0.05 469 0.12** 470
Extraversion –0.23*** 468 0.12** 468 0.14** 469
aQuality of life was not assessed in the whole study sample.
*p < 0.05; **p < 0.01; ***p < 0.001.
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In contrast, the construct body attention is hypothesized 
and operationalized to be more related to mindfulness 
and perhaps a broad awareness of, or sensitivity to, sig-
nals in general. When this sensitivity is accompanied by 
excessive worrying about bodily signals, this process 
may become maladaptive, as in health anxiety (15). 
Future research should examine these hypotheses and 
constructs further. The body ignorance subscale was 
found to be associated with more physical symptoms 
of itch, pain, and fatigue, as well as more scratching 
behaviour. Because treatment of chronic skin condi-
tions relies heavily on adequate self-care behaviour 
and treatment compliance (11), being aware of bodily 
sensations and taking appropriate action may be es-
pecially important in this population. In addition, not 
being conscious of bodily sensations such as itch could 
also lead to unaware, automatic ways of dealing with 
these sensations, for instance through more frequent 
automatic scratching behaviour. Scratching may cause 
further damage to the skin and lead to more itch, a 
process called the itch-scratch cycle. 
Body ignorance was also found to be correlated with 
psychological wellbeing; patients not recognizing or ig-
noring bodily signals were found to be more anxious and 
depressed. In addition, they scored higher on generally 
maladaptive personality traits and coping styles. These 
findings may suggest that patients who do not recognize 
or pay attention to their bodily signals may be at risk 
for psychological problems. This may be relevant not 
only for patient wellbeing, but also for dermatological 
treatment outcomes, as it is known that psychological 
distress plays a significant role in the exacerbation of 
psoriasis (50). An alternative explanation could be that 
patients with high levels of psychological distress may 
be less aware of their bodily signals as they are focused 
on exaggerated worries of, for example, health anxiety. 
Further research is needed on the association between 
body awareness in its current conceptualization and 
these distress-related constructs of health anxiety and 
hyper-vigilance, which are known to be associated with 
both increased symptom reporting and increased atten-
tion to bodily signals (e.g. 17). 
The BAIAS was also found to be correlated with 
sociodemographic variables; women scored slightly 
higher than men on the body awareness subscale, and a 
higher educational level was slightly associated with lo-
wer levels of body ignorance and higher levels of body 
attention. These results correspond with the notion that 
women (51) and individuals with a higher educational 
level (52) have also been found to score lower on the 
related emotion regulation construct alexithymia. 
The findings of this study should be considered in 
light of its limitations, which may be addressed in 
future research. Firstly, as this is the first study on this 
newly developed questionnaire, the BAIAS should 
be further validated based on these results. Also, this 
study was conducted in a sample of psoriasis patients 
with relatively mild to moderate disease severity from 
various hospitals, which raises the issue of representa-
tiveness and possible floor effects in the development 
of the questionnaire. However, all 3 body awareness 
subscales showed a normal distribution and few par-
ticipants scored the highest or lowest possible values, 
indicating that floor effects were not likely to be a pro-
blem. Moreover, none of the 3 body awareness scales 
correlated with disease severity. In addition, disease 
severity in psoriasis is known to be, on average, mild 
to moderate in general practice (e.g. 6, 53). However, 
in order to generalize beyond this group, studies need to 
be conducted that replicate these results in patients with 
more severe disease activity, other chronic conditions, 
such as atopic dermatitis, and healthy participants. The 
developed questionnaire should also be administered 
to other independent samples to confirm its factor 
structure and further test its psychometric properties, 
such as test-retest reliability and sensitivity to change. 
In addition, it would be informative to perform a qua-
litative assessment on comprehension of the scale for 
respondents with diverse educational levels and cultural 
backgrounds, in order to examine whether the scale is 
equally comprehensible for all respondents.
Secondly, a substantial part of our sample had a co-
morbid medical condition. As research clearly suggests 
that psoriasis patients are at an increased risk for several 
other chronic somatic conditions, such as diabetes and 
cardiovascular conditions (see for an overview: 54), ex-
cluding these patients would leave us with a sample that 
would probably not be very clinically representative. 
However, this leaves the possibility that differences in 
body awareness according to medical conditions may 
have influenced our results. For example, diabetics 
are taught to be attuned to physiological sensations as 
they need to detect possible hypoglycaemia in an early 
stage. Even though in the current study no differences 
in body awareness between patients with and without 
these medical conditions were observed, future studies 
should shed more light on this matter.
Thirdly, while correlations between the body igno-
rance scale and psychological and physical functioning 
were consistently in the same direction, the magnitude 
of the correlations was generally small to moderate. 
This corresponds with the knowledge that a multitude 
of factors can contribute to poor physical and psycho-
logical wellbeing, with body awareness being one of 
these factors. Lastly, the cross-sectional nature of this 
study precludes causal conclusions. While it could be 
hypothesized that a low awareness of bodily signals 
leads to poorer self-care behaviour and, therefore, 
poorer skin status and lower physical and psychological 
wellbeing, alternative hypotheses cannot be ruled out. 
Future prospective studies should disentangle the causal 
pathways between body awareness and wellbeing.
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In conclusion, the current study provided new insights 
into the potential relevance of body ignorance, body 
attention, and body awareness, which can be reliably 
measured with the BAIAS. Body ignorance was found 
to be associated with worse physical and psychological 
functioning. If it is proven that body ignorance is pre-
dictive of worse functioning in longitudinal studies, the 
BAIAS may be useful in assessment and screening for 
body ignorance in patients with psoriasis. Subsequently, 
psychological interventions, such as mindfulness or body 
awareness training, may be helpful in reducing body 
ignorance and improving body attention and awareness 
in an adequate manner (55–59).
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